Kardorisso Asandeutertinib Application Scope

Asandeutertinib Mesylate Tablets are indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations and central nervous system (CNS) metastases.

Asandeutertinib Characteristics

Ingredients: The active ingredient is asandeutertinib mesylate.
Properties: A white to off-white film-coated tablet.
Packaging Specification: 40 mg per tablet, 30 tablets per box.
Storage: Store the medicine according to the specified storage conditions.
Expiry Date: The expiry date is indicated on the product packaging.
Executive Standard: The product complies with the applicable pharmaceutical quality standard.
Approval Number: The NMPA approval number is H20260058.
Date of Revision: Refer to the latest approved package insert for the revision date.
Manufacturer: TYK Medicines, Inc

Guidelines for the Use of Kardorisso

Dosage and Administration:
- Recommended Dose: The recommended dose is 160 mg once daily.
- Administration: Kardorisso is administered orally once daily and may be taken with or without food, as directed in the prescribing information.
- Missed Dose: If a dose is missed, take the next scheduled dose as directed and do not double the dose.
Adverse Reactions:
- Common Adverse Reactions: Common adverse reactions may include decreased white blood cell count, decreased neutrophil count, anemia, increased creatine phosphokinase, and diarrhea.
- Serious Adverse Reactions: Serious adverse reactions may occur during treatment and should be managed according to the prescribing information.
Contraindications: Kardorisso is contraindicated in patients with a known hypersensitivity to asandeutertinib or any of its ingredients.
Precautions:
- Patients should use Kardorisso strictly according to the prescribing information.
- Patients should be monitored regularly for adverse reactions during treatment.
- Patients should inform their healthcare provider about all medicines and supplements they are taking.
- Patients should seek medical attention if serious or persistent adverse reactions occur.

Asandeutertinib Interactions

Drug Interactions: Patients should inform their healthcare provider of all medicines they are currently taking.
CYP3A-Related Interactions: Concomitant use with strong CYP3A inhibitors or inducers should be managed according to the prescribing information.
Other Medicines: Potential interactions with other medicines should be assessed by a healthcare professional before use.
Supplements: Patients should also report any vitamins, herbal products, or dietary supplements they are taking.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.